Granules India (GRANULES.NS) Stock Price
Granules India Price
Over the last 19 years Granules India grew revenue by 18.5% annually, reaching 44.82 B INR. Earnings per share have grown at 21.1% per year over the last 19 years. For Granules India, the net margin of 11.2% is down versus 17.0% a few years ago. At today's price the dividend yield works out to roughly 0.18%. The payout ratio is around 7% of earnings. The dividend has grown at 15.7% per year over the past 17 years. The consensus 12-month price target for Granules India is 644.64 INR, about 21.7% below where the stock trades today. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.
Granules India stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Granules India business model & stock analysis
Frequently asked questions about Granules India
Granules India Ltd operates under a business model that focuses on pharmaceutical manufacturing. The company specializes in the production and distribution of active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). With an extensive portfolio of products, Granules India Ltd caters to both domestic and international markets. By leveraging their strong research and development capabilities, the company ensures the highest quality standards in drug manufacturing. Granules India Ltd's commitment to innovation and customer-centric approach has established them as a leading player in the pharmaceutical industry.
Granules India Ltd is primarily active in the pharmaceutical industry. With its focus on manufacturing and exporting pharmaceutical products, the company plays a crucial role in the healthcare sector. Granules India Ltd has established itself as a leading player in the global pharmaceutical market, providing high-quality active pharmaceutical ingredients (APIs), intermediates, and finished dosages to customers worldwide. The company's commitment to innovation, quality, and customer satisfaction has contributed to its success and growth in the highly competitive pharmaceutical industry. Granules India Ltd continuously strives to meet the healthcare needs of patients by providing affordable and effective medicines.
The main competitors of Granules India Ltd in the market include Aurobindo Pharma Ltd, Divis Laboratories Ltd, and Dr. Reddy's Laboratories Ltd.
Granules India Ltd is a leading pharmaceutical company that specializes in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Established in 1984, Granules India Ltd has grown exponentially over the years and is now recognized as one of India's largest vertically integrated pharmaceutical manufacturers. With a strong focus on research and development, Granules India Ltd has successfully developed and commercialized numerous products for various therapeutic segments. The company's commitment to quality, innovation, and customer satisfaction has positioned it as a trusted global player in the pharmaceutical industry. Granules India Ltd continues to expand its product portfolio and strengthen its presence in both domestic and international markets.
Granules India Ltd has achieved several significant milestones in its journey. The company has successfully established itself as a leading manufacturer of pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs). With a focus on innovation and quality, Granules India Ltd has received multiple certifications, including EU GMP and US FDA approvals for its manufacturing units. The company has also expanded its presence globally, with a strong customer base across various countries. Additionally, Granules India Ltd has consistently shown robust financial performance, with steady revenue growth and improved profitability. These achievements highlight the company's commitment to excellence and make it a trusted name in the pharmaceutical industry.
Granules India Ltd is primarily present in India, as it is an Indian pharmaceutical company. It has established a strong presence in the domestic market and has been serving the healthcare needs of millions of people in the country. With its state-of-the-art manufacturing facilities located across various regions in India, Granules India Ltd has successfully catered to the growing demand for high-quality pharmaceutical products. Additionally, the company has also expanded its global footprint and has a significant presence in several countries worldwide, including the United States, Europe, and Asia, through its diverse customer base and strategic partnerships.
Granules India Ltd represents values of integrity, quality, and patient-centricity. With a corporate philosophy focused on innovation and customer satisfaction, the company strives to provide cost-effective and high-quality pharmaceutical products. Granules India Ltd emphasizes on continuous improvement, ethical business practices, and delivering value to all stakeholders. The company's commitment to research, development, and regulatory compliance highlights its dedication to providing safe and effective healthcare solutions. Through its customer-centric approach and consistent growth, Granules India Ltd has established itself as a leading player in the pharmaceutical industry.
Analysts currently set an average price target of 643.62 INR for the Granules India stock (median: 644.64 INR), implying -21.9 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Granules India stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Granules India to generate revenue of 52.98 B INR and earnings per share of 23.00 INR.
Converted at the current exchange rate, the Granules India share trades at 7.76 EUR (823.80 INR).
The Granules India share (GRANULES.NS) is listed on 2 stock exchanges, including: NSE (Indien) (GRANULES.NS).
Granules India Ltd is a leading company in the pharmaceutical active ingredient and formulation industry, headquartered in Hyderabad, India. It started as a small company in 1984 and has grown into a multinational company operating in over 60 countries. The business areas of Granules India include pharmaceutical active ingredients, dosage forms, research and development, as well as equipment and supplies. The company is a major player in the manufacturing of generic drugs, which provide a cost-effective alternative to more expensive patented medications. Pharmaceutical active ingredients: Granules India produces a wide range of pharmaceutical active ingredients used in various medical applications, including pain management, metabolic disorders, cardiovascular and infectious diseases. The company has a strong expertise in manufacturing active ingredients for novel drugs and offers a wide range of products in different therapy areas. Dosage forms: The company also produces a variety of dosage forms such as tablets, capsules, granules, and powders, which allow for the delivery of active ingredients in the desired quantity and dosage to the patient. Granules India works closely with its customers to develop customized solutions for their specific requirements. Research and development: Granules India maintains an extensive research and development department specializing in the development and manufacturing of novel active ingredients and formulations. The company is committed to seeking new technologies and techniques to produce better pharmaceutical products that are more effective and safer. Equipment and supplies: Granules India also has a department for equipment and supplies that support the manufacturing of pharmaceutical products. They manufacture machines and equipment used by other pharmaceutical companies to produce their products. They also offer specialized services such as installation, maintenance, and repair of these equipment. Granules India is also a key player in the development of biosimilars approved by the Food and Drug Administration (FDA). The company also develops and manufactures topical medications such as ointments, gels, and creams, which treat skin issues and infections. Overall, Granules India has an impressive business model and offers a wide range of pharmaceutical products and services. The company has focused on quality, collaboration, and innovation, and is able to provide tailored solutions to its customers' specific needs.
The expected revenue of Granules India is 52.98 B INR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Granules India is 5.58 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Granules India is currently 35.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Granules India stock.
The price-to-sales ratio (P/S) of Granules India is currently 3.77. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Granules India stock.
The Eulerpool Quality Score for Granules India is 8/10.
The ISIN of Granules India is INE101D01020. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Granules India is GRANULES.NS. The ticker symbol is used to trade Granules India shares on the stock exchange.
Granules India stock
Granules India Peer Group
Granules India Ticker
Granules India FIGI
All fundamentals and in-depth analysis of Granules India
Our stock analysis for Granules India stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Granules India. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.